Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-068040
Filing Date
2025-05-09
Accepted
2025-05-09 16:15:20
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atha-20250331.htm   iXBRL 10-Q 2212745
2 EX-31.1 atha-ex31_1.htm EX-31.1 17177
3 EX-31.2 atha-ex31_2.htm EX-31.2 17068
4 EX-32.1 atha-ex32_1.htm EX-32.1 9898
5 EX-32.2 atha-ex32_2.htm EX-32.2 8605
6 GRAPHIC img107087971_0.jpg GRAPHIC 215776
  Complete submission text file 0000950170-25-068040.txt   8274426

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atha-20250331.xsd EX-101.SCH 864457
69 EXTRACTED XBRL INSTANCE DOCUMENT atha-20250331_htm.xml XML 1335944
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

EIN.: 453368487 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39503 | Film No.: 25930610
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)